Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0RLKMU
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
IBI-343
|
|||||
| Synonyms |
IBI 343; IBI-343; IBI343
Click to Show/Hide
|
|||||
| Organization |
Innovent Biologics, Inc.
|
|||||
| Drug Status |
Phase 3
|
|||||
| Indication |
In total 2 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
A fully humanized anti-CLDN18.2 monoclonal antibody
|
Antibody Info | ||||
| Antigen Name |
Claudin-18.2 (CLDN18.2)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Conjugate Type |
Non-natural Amino Acids
|
|||||
